HGH Fragment 176-191
Quick summary
A fragment from the C-terminal end of human growth hormone, studied for its effects on fat metabolism without growth hormone's broader effects. Research focus: lipolysis models and adipose metabolism. This page leads with SRP's low-and-slow starting dose.
Overview
A fragment from the C-terminal end of human growth hormone, studied for its effects on fat metabolism without growth hormone's broader effects.
Looking for research material? Simple Research Peptides lists HGH Fragment 176-191 5mg Research Peptide Vial for laboratory research use.
Mechanism
The fragment of growth hormone that carries most of its fat-burning activity in rodent studies.
Research areas
- lipolysis models
- adipose metabolism
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Low end of the studied range: 250 mcg; 250 mcg; 250 mcg; 250 mcg. |
|---|---|
| Frequency | Reported schedules: 1–2x daily, fasted; 250–500mcg daily, split 2x; Daily. |
| Reconstitution | Examples: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL; 5 mg vial + 2 mL water = 2.5 mg/mL; 5mg vial + 2mL diluent (as listed). storage note: Reconstituted: refrigerate, used within 4 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Top of the studied range: 500 mcg; 500 mcg; 500 mcg; 500 mcg. These are range tops, not verified ceilings. |
|---|
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is HGH Fragment 176-191 studied for?
In research it is studied for lipolysis models and adipose metabolism. The fragment of growth hormone that carries most of its fat-burning activity in rodent studies.
How is HGH Fragment 176-191 given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026